Literature DB >> 10582935

Management of Crohn's disease.

D S Rampton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10582935      PMCID： PMC1117206          DOI： 10.1136/bmj.319.7223.1480

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  46 in total

1.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Authors:  P Rutgeerts; G D'Haens; S Targan; E Vasiliauskas; S B Hanauer; D H Present; L Mayer; R A Van Hogezand; T Braakman; K L DeWoody; T F Schaible; S J Van Deventer
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

2.  Cancer in Crohn's disease: dispelling the myths.

Authors:  D B Sachar
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

3.  A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.

Authors:  W J Tremaine; K W Schroeder; J M Harrison; A R Zinsmeister
Journal:  J Clin Gastroenterol       Date:  1994-12       Impact factor: 3.062

4.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.

Authors:  J W Singleton; S B Hanauer; G L Gitnick; M A Peppercorn; M G Robinson; L D Wruble; E L Krawitt
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

5.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.

Authors:  W R Connell; M A Kamm; J K Ritchie; J E Lennard-Jones
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

Review 6.  Review article: practical management of the short bowel.

Authors:  J E Lennard-Jones
Journal:  Aliment Pharmacol Ther       Date:  1994-12       Impact factor: 8.171

7.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.

Authors:  B G Feagan; J Rochon; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; R Gillies; M Hopkins
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

8.  Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease.

Authors:  H J Kaufmann; H L Taubin
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

9.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.

Authors:  W R Connell; M A Kamm; M Dickson; A M Balkwill; J K Ritchie; J E Lennard-Jones
Journal:  Lancet       Date:  1994-05-21       Impact factor: 79.321

10.  A comparison of budesonide with prednisolone for active Crohn's disease.

Authors:  P Rutgeerts; R Löfberg; H Malchow; C Lamers; G Olaison; D Jewell; A Danielsson; H Goebell; O O Thomsen; H Lorenz-Meyer
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245
View more
  10 in total

1.  Management of difficult inflammatory bowel disease: where are we now?

Authors:  DS Rampton
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

Review 2.  An update of the role of nutritional therapy in the management of Crohn's disease.

Authors:  Moftah H Alhagamhmad; Andrew S Day; Daniel A Lemberg; Steven T Leach
Journal:  J Gastroenterol       Date:  2012-06-15       Impact factor: 7.527

3.  Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.

Authors:  C Romano; S Cucchiara; A Barabino; V Annese; C Sferlazzas
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

Review 4.  Review of the use of intralesional steroid injections in the management of ileocolonic Crohn's strictures.

Authors:  Roisin Bevan; Colin J Rees; Matthew D Rutter; David A L Macafee
Journal:  Frontline Gastroenterol       Date:  2013-03-27

5.  New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer via small molecule potentiators.

Authors:  Chamitha Weeramange; Ashabha Lansakara; Johnathan Dallman; Thi Nguyen; Wasundara Hulangamuwa; Ryan J Rafferty
Journal:  Medchemcomm       Date:  2019-03-18       Impact factor: 3.597

6.  Service evaluation of patients with orofacial granulomatosis and patients with oral Crohn's disease attending a paediatric oral medicine clinic.

Authors:  J L Howell; R M Bussell; A M Hegarty; H Zaitoun
Journal:  Eur Arch Paediatr Dent       Date:  2012-08

Review 7.  Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.

Authors:  A K Akobeng; M Zachos
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 8.  Stem cells in clinical practice: applications and warnings.

Authors:  Daniele Lodi; Tommaso Iannitti; Beniamino Palmieri
Journal:  J Exp Clin Cancer Res       Date:  2011-01-17

9.  Ultrasound, CT and FDG PET-CT of a duodenal granuloma in a dog.

Authors:  Sunghoon Jeon; Seong Young Kwon; Rohani Cena; Ju-hwan Lee; Kyoung-oh Cho; Jung-Joon Min; Jihye Choi
Journal:  J Vet Med Sci       Date:  2014-04-18       Impact factor: 1.267

Review 10.  Stem Cell Applications for Treatment of Cancer and Autoimmune Diseases: Its Promises, Obstacles, and Future Perspectives.

Authors:  Yousef M Hawsawi; Faisal Al-Zahrani; Charalampos Harris Mavromatis; Mohammed A Baghdadi; Shalini Saggu; Atif Abdulwahab A Oyouni
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.